DSS, Inc. is a globally diversified enterprise with operations across numerous industries. In product packaging, the company specializes in manufacturing and distributing custom folding cartons, mailers, photo sleeves, and advanced three-dimensional direct mail products. It also engages in the marketing and distribution of nutritional and personal care items. Within the biotechnology and biohealth sphere, DSS makes strategic investments in and acquires companies dedicated to pioneering drug discovery, prevention, and treatment methodologies for neurological, oncological, and immune-system diseases. Furthermore, it develops innovative open-air defense systems designed to combat airborne infectious agents like tuberculosis and influenza. The firm's financial services and commercial lending activities involve acquiring equity positions in undervalued commercial banks, bank holding companies, and licensed non-banking financial institutions. Its related non-banking ventures include loan syndication, mortgage banking, trust and escrow services, banking technology solutions, loan servicing, equipment leasing, problem asset management, consulting for special purpose acquisition companies (SPACs), and advisory capital raising services. For securities and investment management, DSS offers a range of services, including managing a real estate investment trust (REIT) focused on acquiring hospitals and various acute and post-acute care facilities, with an emphasis on fostering healthy living communities. The company also develops and invests in assets within the securities trading and fund management sectors, and operates as a broker-dealer for digital assets. In the alternative energy sector, DSS provides solutions such as solar farms, solar battery storage systems, and services for residential energy generation and storage. Established in 1984, the company was formerly known as Document Security Systems, Inc. before officially changing its name to DSS, Inc. in September 2021. Its headquarters are located in West Henrietta, New York.
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
DSS, Inc. announced that Zoar Limited has filed a Form F-4 registration statement with the SEC in connection with Impact Biomedical's proposed business combination with Zoar.
DSS is a significant stockholder of Impact Biomedical (NYSE American: IBO), and CEO Jason Grady characterized the filing as continued momentum that could ultimately create meaningful value for DSS and its shareholders.
Completion remains contingent on the SEC declaring the registration statement effective, Impact stockholder approval, and NYSE American listing of Zoar ordinary shares, so the transaction and any value to DSS are not assured.